Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1Not yet recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Pancreatic Neoplasms 21Urinary Bladder Neoplasms 8Biliary Tract Neoplasms 7Non-Muscle Invasive Bladder Neoplasms 6Nasopharyngeal Carcinoma 6Nasopharyngeal Neoplasms 5Cholangiocarcinoma 5Ovarian Neoplasms 3Neoplasms 3Carcinoma, Non-Small-Cell Lung 3Breast Neoplasms 3Triple Negative Breast Neoplasms 2Recurrence 2Pancreatic Cancer Resectable 2Neoplasm Metastasis 2Lymphoma, Extranodal NK-T-Cell 2Thyroid Neoplasms 1Rhabdoid Tumor 1Recurrent Platinum-Sensitive Fallopian Tube Endometrioid Adenocarcinoma 1Rare Tumour 1Pancreatic cancer, adult 1Pancreatic Cancer Non-resectable 1PDAC - Pancreatic Ductal Adenocarcinoma 1Mibc 1Melanoma 1Lung Neoplasms 1Lung Diseases, Interstitial 1Locally Advanced Pancreatic Cancer 1Liver Neoplasms 1Klatskin Tumor 1

Interventions

Gemcitabine 1130-nm albumin-bound paclitaxel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Not yet recruiting × Anophthalmia with pulmonary hypoplasia × Gemcitabine × Clear all
NCT06361030 2024-04-11

Surufatinib Combined With Gemcitabine Plus Nab-paclitaxel in Locally Advanced Pancreatic Cancer

Union Hospital, Tongji Medical College, Huazhong University of Science and Technology

Phase 2 Not yet recruiting
40 enrolled
Gastrointestinal

Anophthalmia with pulmonary hypoplasia, Pancreatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡